Hormonal
Incretin-based therapies (liraglutide, semaglutide, tirzepatide) produce significant body weight reduction (≥5% in majority of patients) and reduce the 10-year relative risk of type 2 diabetes development by 60-69% in individuals with obesity.
If you have obesity or overweight with related health issues, incretin-based medications (like semaglutide or tirzepatide) are highly effective for significant weight loss and preventing type 2 diabetes. They work by mimicking hormones that regulate appetite and are taken weekly (or daily for liraglutide) alongside lifestyle changes. These are not quick fixes but long-term treatments requiring continuous use to maintain results.
Incretin-based therapies have been associated with a body weight (BW) reduction of ≥5% in at least half of patients in most randomized controlled trials (RCT) and real-world studies (RWS). Semaglutide and tirzepatide have also displayed a mean 60–69% 10-years relative risk reduction of T2D development.
Why this rating
Supported by multiple Phase 3 RCTs (SCALE, STEP, SURMOUNT) and real-world studies.
Source
Incretin-based therapies for the treatment of obesity-related diseases
Irene Caruso et al. · npj Metabolic Health and Disease · 2024
DOI 10.1038/s44324-024-00030-5
More from this paper
- Incretin-based therapies improve cardiovascular risk factors (lipids, blood pressure) and reduce the risk of major cardiovascular events and heart failure in individuals with obesity.Strong
- Tirzepatide demonstrates superior body weight reduction compared to semaglutide 2.4 mg and liraglutide 3.0 mg in non-diabetic subjects with obesity.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →